BCL2 and diffuse large B-cell lymphoma: Moreover, among the DLBCL NOS, the immunohistochemical co-expression of MYC and BCL2, deemed biologically and clinically relevant, identifies the category of double-expressor disease, harboring an unfavorable prognostic impact [27].